



GENORACLE

SLU-PP-332

Purity: >98% | Molecular Formula: C₁₈H₁₄N₂O₂

Molecular Weight: 290.32

DESCRIPTION:

SLU-PP-332 is a small, selective, membrane-permeable molecule classified as an **exercise mimetic** due to its ability to replicate key molecular effects of endurance training. It functions as a potent agonist of the **estrogen-related receptors (ERR α , ERR β , and ERR γ)**—nuclear receptors involved in regulating cellular metabolism, mitochondrial biogenesis, and fatty acid oxidation.

Unlike classical estrogenic compounds, SLU-PP-332 does **not bind to estrogen receptors ER α /ER β** , reducing the risk of hormonal side

effects. Its activation of the ERR-PGC-1 α pathway leads to the upregulation of genes associated with oxidative metabolism, energy production, and muscle adaptation.

This novel compound is being investigated for its potential to enhance physical performance, increase endurance, support metabolic health, and improve mitochondrial function—making it a promising candidate for managing **age-related decline, obesity, and chronic fatigue**.

PROTOCOL:

Content & Potency: 500mcg capsule provided in a quantity of 60 capsules

Oral: Take 1-2 capsules daily

CLINICAL RESEARCH:

SLU-PP-332: A Synthetic ERR Agonist Alleviates Metabolic Syndrome

In a 2024 study published in *The Journal of Pharmacology and Experimental Therapeutics*, researchers investigated the effects of SLU-PP-332, a synthetic agonist of ERR α , β , and γ , in mouse models of obesity and metabolic syndrome. SLU-PP-332 administration mimicked many of the metabolic benefits of aerobic exercise, including increased energy expenditure, enhanced fatty acid oxidation, and reduced fat mass accumulation.

The treatment significantly improved Insulin sensitivity and reduced obesity without

altering food intake. These findings highlight SLU-PP-332's potential as a pharmacological exercise mimetic and a promising therapeutic candidate for metabolic disorders.

“An estrogen receptor-related orphan receptor agonist, SLU-PP-332, with exercise mimetic activity, holds promise as a therapeutic to treat metabolic diseases by decreasing fat mass in mouse models of obesity.”

GENORACLE